bearish
Pre-IPO New Horizon Health (NHH.HK) - Here Are the Concerns
393 Views03 Dec 2020 09:28
This article summarized the concerns for the New Horizon Health in terms of product commercialization, penetration rate of core products, financial position and other concerns.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- Pre-IPO Zhaoke Ophthalmology Pharmaceutical - It Remains to Be Seen How to Find Its Way Out09 Mar 2021
- China Healthcare Weekly (Mar.5)07 Mar 2021
- New Horizon Health (6606.HK) - Still Has a Long Way to Go04 Mar 2021
- Pre-IPO New Horizon Health (NHH.HK) - Here Are the Concerns03 Dec 2020
- Pre-IPO Harbour Biomed (2142.HK) - Don't Ignore The "Hidden Value"01 Dec 2020
- Pre-IPO Edding Group - Strong Core Products but Still Have Concerns26 Nov 2020
- 2021 High Conviction - Investment Opportunities in China Healthcare Industry23 Nov 2020
x